Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRITON
2023-510172-31-00Phase 3Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing CHF 5993 triple therapy with CHF 1535 dual therapy (2 arms). Primary endpoint: Change from baseline in pre-dose morning FEV1 at week 28. Started Jun 2024; status: completed.
02
Drugs
beclometasone dipropionate/formoterol fumarate/glycopyrroniumbeclometasone dipropionate + formoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2023-510172-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510172-31-00.